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Abstract: The objective of this study was to review the current knowledge about the use of 
orlistat from clinical and economic perspectives, and to assess this drug’s public health impact. 
Weight reduction by current antiobesity drugs, compared to placebo, is at most around 5 kg. 
Orlistat, the most studied antiobesity drug, is associated with the least-severe adverse effects, but 
compared with other drugs in its class it also delivers the most modest weight loss versus placebo 
(less than 3 kg). Orlistat appears to have a favorable risk/benefit profile, and cost-effectiveness 
ratios seem to be within a range that is generally considered acceptable. In the short-term, 
orlistat is related to reduced diabetes incidence and to slightly improved blood pressure and 
lipid profiles. Long-term clinical effects have been largely unstudied, however, and this study 
did not find reports that considered mortality as an endpoint. Given a very low continuation with 
orlistat treatment in the population and very modest and, apparently, only short-term clinical 
effects, orlistat is not likely to have a significant impact on the population health. Public health 
approaches of improving environmental and social factors to foster healthier food choices and 
increase physical activity remain essential for addressing the obesity epidemic.
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Introduction
In most developed countries, obesity has become an epidemic of alarming proportions 
and a leading public health concern. Obesity is defined as a body mass index (BMI) 
of 30 kg/m2 or greater. A BMI between 25 and 29.9 kg/m2 is termed overweight. In 
the United States, overweight/obesity in children is defined as a BMI at or above the 
sex- and age-specific 95th percentile BMI cutoff points from the 2000 CDC Growth 
Charts (Centers for Disease Control and Prevention).1 Since 1980, obesity rates have 
more than doubled among US adults2 and tripled among US children.3 More than 
one third of US adults and 17% of US children are obese.2,3 In the last two decades, 
the prevalence of obesity has also almost doubled in Canada; currently, nearly 23% of 
adult Canadians are obese.4 Obesity is quickly rising in European countries as well; 
according to the most recent available data (covering 1997–2002), the prevalence 
for adults ranges from 6% (Norway) to 20% (Hungary), and rates are highest in 
Central-Eastern Europe.5 Although the prevalence of obesity in China is relatively low 
compared with Western countries, it is the rapid increase of the condition, especially 
among children, that is particularly alarming. The prevalence of overweight and obe-
sity in children aged 7–18 years increased 28 times and obesity increased four times 
between 1985 and 2000 in China.6 Data from the 2002 national nutrition and health 
survey showed that 14.7% of Chinese were overweight (BMI $ 25) and another 2.6% ClinicoEconomics and Outcomes Research 2010:2 submit your manuscript | www.dovepress.com
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were obese (BMI $ 30). Since the Chinese population totals 
1.3 billion, about one fifth of the one billion overweight or 
obese people in the world are Chinese.6 The World Health 
Organization estimates that by the year 2015, approximately 
2.3 billion adults worldwide will be overweight, and more 
than 700   million will be obese.7
In the United States, obesity is a leading actual cause 
of death and is associated with many of the top 10 dis-
eases with the highest mortality rates, including diabetes, 
heart disease, stroke, and cancer.8–10 It has psychological 
and social   consequences, and is a risk factor for some 
respiratory diseases, such as sleep apnea and for many other 
conditions, such as complications during pregnancy. For 
these reasons, effective interventions to treat overweight 
and obesity are much needed, including those with only 
modest effects. Research has shown that even small losses 
in weight, such as 5%–10% of baseline weight, may have 
clinical importance,11,12 and may reduce blood pressure, 
glucose, cholesterol and   triglycerides levels,13–15 potentially 
moderating cardiovascular diseases and diabetes.16–18
Obesity is currently responsible for 2%–8% of health 
costs and 10%–13% of deaths in some parts of Europe.7 
In the United States, the annual medical burden of obesity 
increased from 6.5% of annual medical spending in 1998 to 
9.1% in 2006, possibly amounting to $147   billion per year 
by 2008.19 Another question of concern is who bears the 
costs of obesity? A recent study showed that there may be a 
social welfare loss in a pooled-risk health insurance setting 
as a consequence of nonobese persons paying for medical 
treatment of obese persons. In the United States, this loss 
of social welfare, also known as external cost, was around 
$150 per person.20
Pharmacological treatment of obesity has become 
  widely-used in most countries, although the number of 
available drugs is still very limited. Two drugs, orlistat and 
sibutramine, are currently approved by the US Food and 
Drug Administration (FDA) and European Medical Agency 
(EMEA), and are available for the long-term treatment of 
obesity and overweight in the European Union and the 
United States.21
Orlistat (tetrahydrolipstatin) is a lipase inhibitor that 
blocks about one-third of intestinal fat absorption. Biological 
research on orlistat started over 20 years ago.22 It has been in 
the drug market for a decade as a prescription medicine called 
Xenical (Roche, Basel, Switzerland), and more recently as an 
over-the-counter formulation called Alli (GlaxoSmithKline, 
Brentford, Middlesex, United Kingdom). The latter is sold in 
60 mg capsules, half the dosage of orlistat by prescription.
The objective of this study was to review the current 
knowledge about the use of orlistat from clinical and 
economic perspectives, as well as from a public health 
perspective.
Methods
Twelve databases, including Medline, Embase, PsycInfo, 
EconLit, CINAHL, Web of Science, Cochrane, ERIC, 
Health and Safety Science Abstracts, PILOTS, Social 
  Services Abstracts, and Sociological Abstracts (CSA) were 
searched until August 2009. This search was intended to be as 
  comprehensive as possible; however, this was not a   systematic 
review. The search was limited to English language. Two 
different strategies were used. For the years before 2009, 
both indexed (keyword) and free-text terms were used with 
a boolean logic to establish   relationships between the words 
orlistat and clinical treatment or cost or economic or effective. 
For the year 2009, we used only the term orlistat in our search 
without language restriction. After removing duplicates, a 
total of 712 articles were found. The references of identified 
papers were checked for related articles. Some individual 
articles may not be explicitly cited here if they were included 
in meta-analysis studies that are cited in this review.
Clinical practice guidelines  
for orlistat
Current clinical practice guidelines,23 set by the UK National 
Institute for Clinical Excellence in 2006, stipulate that 
orlistat treatment may be used in adults who meet one of 
the   following criteria:
•	 A BMI of 30 kg/m2 or more.
•	 A BMI of 28 kg/m2 or more when associated risk 
  factors, such as prediabetes, diabetes, hypertension, or 
  cardiovascular diseases, are present. (Previous guidelines 
set the BMI at 27 kg/m2 or more when obesity-associated 
conditions were present).24–26
For people of Asian heritage, the clinical guidelines 
from the American College of Physicians recommend lower 
thresholds for prescribing orlistat treatment: a BMI of 27.5 
without comorbid conditions and 25 to 27.4 with comorbid 
conditions.27
Orlistat should be prescribed only as part of an overall 
plan for managing obesity.24–28 Arrangements should be 
made for appropriate health professionals to offer informa-
tion,   support, and counseling on additional diet, physical 
activity, and behavioral strategies for losing weight, espe-
cially given that not all patients respond to a given obesity 
treatment drug. If a patient has not lost at least 2 kg after ClinicoEconomics and Outcomes Research 2010:2 submit your manuscript | www.dovepress.com
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4 weeks of treatment, the patient is not likely to benefit 
from the drug.24 Therapy should be continued beyond 3 
months only if the person has lost at least 5% of his or her 
initial body weight since starting drug treatment23 (or an 
average of 1 pound {0.45 kg} or more per week26 or 10% 
of weight over a 6-month period24). Rates of weight loss 
may be slower in people with type 2 diabetes, so less strict 
goals may be appropriate for this population. The decision 
to use drug treatment for longer than 12 months (usually 
for weight maintenance) should be made only after discuss-
ing potential benefits and limitations with the patient. The 
co-prescribing of orlistat with other drugs aimed at weight 
reduction is not recommended.
Recommendations for specific medications vary 
  somewhat among guidelines. The American College of 
  Physicians (ACP) argues that data are not sufficient to 
determine whether one drug is more efficacious than 
another when comparing sibutramine, orlistat, phentermine, 
  diethylpropion, fluoxetine, and bupropion.27 In contrast, 
the Singapore   Ministry of Health (SMOH) and the US 
  Department of Veterans Affairs (VA), assert that the research 
evidence identifies orlistat and sibutramine as the drugs with 
the widest efficacy and safety data.28
With regard to duration of treatment, ACP asserts that data 
on long-term (>12 months) efficacy or safety are   insufficient 
to inform the decision to continue treatment beyond 1 
year. However, according to SMOH and VA guidelines, 
sibutramine and orlistat could be considered as a compo-
nent of weight maintenance programs for up to 2 years and 
4 years, respectively.28
Weight loss
Weight loss from pharmacotherapy is generally modest, 
ranging from 2 kg to 10 kg. Weight is usually regained 
after discontinuation of the drug, and generally there is no 
  difference between treatment and placebo groups several 
months after treatment ends.29,30 The longest orlistat study, 
Xenical in the Prevention of Diabetes in Obese Subjects 
(XENDOS),31 found statistically significant mean weight loss 
of 2.8 kg after 4 years’ use of orlistat compared to lifestyle 
changes alone (5.8 kg vs 3 kg mean weight loss, respectively). 
The weight loss was similar between orlistat recipients with 
impaired glucose tolerance (5.7 kg) or normal glucose toler-
ance (5.8 kg) at baseline. This finding is consistent with the 
results of several meta-analyses that indicated the range of 
weight loss with orlistat use to be from 5.5 kg to 9.5 kg.32–35 
This weight loss is usually in the range of 5%–10% of a 
baseline weight.36
The main co-interventions in most weight loss stud-
ies were low-fat, low-energy diet and encouragement to 
  exercise. For example, in the XENDOS study, all patients 
were   prescribed a reduced-calorie diet (about 800 kcal/day 
deficit) containing 30% of calories from fat and not more 
than 300 mg of cholesterol per day. The prescribed energy 
intake was readjusted every 6 months to account for any 
weight lost during the preceding months. Patients were 
also encouraged to walk at least 1 extra kilometer a day in 
addition to their usual physical activity. All patients kept 
physical activity diaries.31 In a recent meta-analysis of long-
term pharmacotherapy for obesity, all of the 16 randomized 
controlled trials (RCTs) of orlistat included low-fat, low-
calorie diet; 5 studies included exercise counseling; and 2 
studies included exercise in addition to diet.33 Although the 
diet/exercise co-interventions were standardized within each 
individual study, the comparability across trials for these 
interventions is not clear.
The use of orlistat increased the absolute percentage of 
participants achieving 5% and 10% weight loss thresholds by 
21% (pooled results of 14 RCTs) and 12% (pooled results of 
13 RCTs) respectively compared to placebo.33 Orlistat therapy 
increased the odds of attaining $5% weight loss compared to 
diet-only therapy after 1 year by an odds ratio (OR) of 2.54 
(95% confidence interval [CI]: 2.17–2.90) (pooled results 
of 10 RCTs), and after 2 years by an OR of 4.55 (95% CI: 
1.99–10.4) (pooled results of two RCTs).37
A meta-analysis of head-to-head studies comparing 
orlistat and sibutramine indicated that sibutramine was sig-
nificantly more efficacious for achieving weight loss than 
orlistat, with the weighted mean difference in weight loss 
of 2.2 kg favoring sibutramine.32 However, sibutramine has 
more serious side-effects than orlistat.
The weight loss effects of orlistat on patients with 
diabetes were slightly lower than those without diabetes: 
  placebo-subtracted weight loss was 2.3 kg (1.6 kg to 3 kg; 
based on four studies) in patients with diabetes compared 
to 2.9 kg (2.5 kg to 3.2 kg; based on 15 studies) in patients 
without diabetes.33 Persons with diabetes also seem to regain 
their weight more rapidly, although the mechanisms for this 
are unclear and the validity of this observation has not been 
systematically examined.33,38,39
The effectiveness of orlistat or sibutramine on   countering 
weight gain induced by antipsychotic drugs has not been studied 
yet. In individuals with established weight gain and metabolic 
issues, switching to an antipsychotic agent with lower weight 
gain potential and/or lifestyle modifications with physical activ-
ity are most effective in promoting weight loss.40ClinicoEconomics and Outcomes Research 2010:2 submit your manuscript | www.dovepress.com
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Clinical considerations
Modest weight loss in the obese of between 5% and 
10% of body weight is associated with improvements in 
  cardiovascular risk profiles and reduced incidence of type 2 
diabetes.12,35,41 However, treatment success, when defined as 
clinically meaningful weight loss that can be maintained for 
longer periods, has been limited.42–45 Furthermore, a majority 
of obese patients have multiple risk factors for   cardiovascular 
diseases (CVD), including diabetes,   prediabetes, hyperten-
sion, and dyslipidemia. The   complex course of treatment 
for these conditions complicates behavioral change aimed 
at weight reduction. The clinical guidelines on obesity treat-
ment state that the control of CVD should be given the same 
emphasis as weight-loss therapy because risk factors for 
CVD can be reduced whether or not weight loss efforts are 
successful.24
One empirical question is whether statistically-significant 
differences in weight loss observed between orlistat treat-
ment and placebo have clinical significance. Findings of a 
recent meta-analysis suggested that weight loss of $5% 
was not consistently-associated with improvements in 
  cardiovascular risk factors and appeared to be intervention-
specific.37 Improvements were seen mainly in high-risk 
groups, because changes in risk factors were more likely in 
subjects with abnormal baseline levels. This was consistent 
with findings from observational studies that intentional 
weight loss was associated with increased longevity, but 
only in people with pre-existing disease.46,47
Clinical effects in patients  
with type 2 diabetes mellitus
Obese patients who have diabetes are considered to be at very 
high absolute risk for mortality.29 Their life expectancy may 
be shortened by as much as 15 years, with up to 75% dying 
of macrovascular complications.48
Orlistat is shown to reduce the incidence of diabetes.31,33,49 
Compared with lifestyle changes alone, adding orlistat 
changed the cumulative incidence of diabetes from 9% 
with placebo to 6.2% with orlistat, corresponding to a risk 
reduction of 37.3% (P = 0.0032) over 4 years of treatment.31 
The preventive effect was explained by differences in study 
participants with impaired glucose tolerance, among whom 
both lifestyle interventions and orlistat reduced the rate of 
progression to type 2 diabetes mellitus.49 However, lifestyle 
interventions seemed to be at least as effective as orlistat: the 
pooled hazard ratios were 0.51 (95% CI: 0.44 to 0.60) for 
lifestyle interventions versus standard advice, and 0.44 (95% 
CI: 0.28 to 0.69) for orlistat versus the control group.
A large meta-analysis of orlistat with a total of 2036 
  participants and follow-up periods of between 24 and 57 weeks 
indicated that the pooled reduction for glycosylated   hemoglobin 
was 0.5% (95% CI: 0.3 to 0.6);29 previous research has shown 
that 1% absolute reductions in glycosylated hemoglobin lead 
to significant reductions in microvascular complications 
from diabetes.50,51 In the meta-analysis, the pooled reduction 
for   fasting glucose was 0.8 mmol/L (95% CI: −1.1, −0.5).29 
Another meta-analysis37 found that orlistat had inconsistent 
effects on glycemic control: modest but significantly greater 
reductions in fasting blood glucose (0.1–1.7 mmol/L) than 
diet-only therapy in six studies, but no difference in two stud-
ies. The greatest improvements in glycemic control occurred 
in subjects with type 2 diabetes mellitus.52,53
The pooled effects of orlistat treatment in patients with 
diabetes were as follows: total cholesterol, −0.4 mmol/L 
(95% CI: −0.5, −0.3); LDL cholesterol, −0.3 mmol/L (95% 
CI: −0.4, −0.2); triglycerides, −0.2 mmol/L (95% CI: −0.4, 
−0.1); systolic blood pressure (SBP), −3.0 mmHg (95% 
CI: −6.3, 0.3); diastolic blood pressure (DBP), −4.2 mmHg 
(95% CI: −7.8, −0.6).29 It remains unclear whether improved 
glycemic control and lipid levels associated with orlistat use 
can be maintained over the long-term to influence the risk 
of complications.
Clinical effects on cardiovascular  
risk factors
International studies have shown that differences in 
serum cholesterol concentration and dietary saturated fat 
are the most important determinants of the differences 
in mortality from ischemic heart disease between coun-
tries, accounting for over 80% of the total variation.54 
When assessing the significance and effect of orlistat on 
cholesterol, several issues have to be considered. First, 
studies suggest that there is no threshold below which a 
lower serum cholesterol concentration is not associated 
with a lower risk of ischemic heart disease; and second, 
an individual person may have difficulty in lowering 
serum cholesterol concentration through dietary change 
by more than about 0.3 mmol/L. However, it is also 
well documented that at community levels a reduction 
of 0.6 mmol/L (about 10%) in serum concentrations of 
total and low density lipoprotein cholesterol is feasible 
and has occurred through dietary change over periods of 
a few years.54 This level of reduction is associated with 
a decrease in the risk of ischemic heart disease of about 
50% at the age of 40 years, 40% at 50 years, 30% at 
60 years, and 20% at 70 years and over.54ClinicoEconomics and Outcomes Research 2010:2 submit your manuscript | www.dovepress.com
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Finally, a very important consideration is that in the first 
two years after lowering cholesterol little reduction in risk of 
ischemic heart disease occurs, and the full reduction in risk 
of ischemic heart disease is achieved within five years.54
Obesity-associated hypertension is especially difficult 
to treat and puts patients at a substantially increased risk for 
cardiovascular events.55 Weight reduction is recommended in 
major guidelines as the first step in treating hypertension.56 
However, long-term weight reduction, which is necessary 
to sustain blood pressure control, may not be feasible in 
the majority of patients.57 While pharmacological weight-
  reducing interventions with orlistat may lead to reduction 
in blood pressure as well as weight,33,58 additional studies 
are needed to determine the long-term (.1 year) efficacy 
and safety of antihypertensive and antiobesity management 
strategies in overweight and obese hypertensive patients.
A meta-analysis of the effect of weight-reducing 
interventions in hypertensive patients indicated that both 
  diet-based interventions and orlistat reduced blood pressure, 
but diets led to greater reductions than orlistat58 (diet: SBP 
weighted mean difference [WMD], −6.3 mmHg; DBP WMD, 
−3.4 mmHg; orlistat: SBP WMD, −2.5 mmHg; DBP WMD, 
−2.0 mmHg; sibutramine: SBP WMD, +3.2 mmHg). An 
earlier   meta-analysis37 found that orlistat had no significant 
effect on blood pressure compared with dietary/lifestyle-only 
therapy, except in two out of nine studies that measured 
blood pressure, one of which involved subjects with poorly 
controlled hypertension.59
Based on results from 11 RCTs, orlistat therapy was 
associated with significantly-greater reductions in LDL 
levels (0.11–0.38 mmol/L) than diet-only therapy, but in 
most studies there were no significant effects on HDL and 
triglyceride levels.37 Mannucci and colleagues59 found that 
orlistat affected serum lipid profiles in overweight and 
obese subjects, independently of weight loss. In the 15 tri-
als with orlistat, mean weight loss showed a significant cor-
relation with mean reduction of total cholesterol (r = 0.48; 
P , 0.05), which maintained statistical significance after 
adjustment for mean weight loss (B = −2.81 ± 1.28; 
P , 0.05). However, a randomized control study of 180 
Asian patients indicated no significant reductions in total 
cholesterol, LDL, HDL and triglyceride levels after 1 
year of treatment.60 Another study of Chinese patients 
indicated that although there were significant short-term 
reductions in total cholesterol and LDL levels which 
resulted from a 24-week treatment with orlistat, 12 weeks 
after discontinuing the treatment these reductions were no 
longer significant.61
A recent RCT investigated the effect of long-term 
(3.2 year) weight loss on serum levels of the nontraditional 
  cardiovascular risk factors interleukin (IL)-18 and matrix 
metalloproteinase (MMP)-9. It found that orlistat treatment 
had no independent effects on IL-18, MMP-9, or leptin. 
  However, decreases in IL-18 were associated with changes 
in body mass index independent of changes in blood   pressure 
and lipids, indicating that even a minor weight   reduction 
(.5%) has beneficial effects on these nontraditional 
  cardiovascular risk markers.62
No studies were found that assessed the association of 
orlistat on all-cause or specific-cause mortality. Research 
findings on the association between any type of intentional 
weight loss and mortality are mixed.15,46,47,63–66 A   prospective 
cohort study which used a probability sample of the US 
population found that self-reported intention to lose weight 
was associated with lower all-cause mortality, independent 
of weight change, perhaps because weight loss attempts were 
a marker of other healthy behaviors.67
Weight regain
The majority of obese patients regain most of the weight   initially 
lost in successful interventions,29,30 regardless of orlistat use.68 
In nondiabetic populations,   comprehensive, intensive group 
behavioral programs without   pharmacotherapy produced mean 
losses of 8 kg to 10 kg at six months, with a regain of 30% to 
35% of weight loss at one year, and 50% of participants returned 
to baseline weight by 3 to 5 years.43,45 A recent meta-analysis of 
RCTs of long-term   pharmacotherapy showed that participants 
in both orlistat and placebo arms showed similar amounts of 
weight regain, though the weight differential observed after the 
weight-loss phase was preserved.33
Weight regain was studied in a 3-year Scandinavian 
multicenter RCT of obese patients with metabolic risk 
  factors such as dyslipidemia, impaired fasting glucose, 
and   diet-treated type 2 diabetes.42 Initially an 8-week 
  very-low-energy diet induced weight loss of 14.4 ± 2 kg. 
Those who lost $5% of their body weight (309 of 383) 
were then   randomized to receive lifestyle counseling for 
3 years together with either orlistat 120 mg three times a 
day or matching placebo capsules. The addition of orlistat 
was associated with maintenance of an extra 2.4 kg weight 
loss for up to 3 years. However, a subsequent retrospective 
study revealed that the use of orlistat compared with placebo 
in a subgroup of the Scandinavian study population did not 
appear to influence dietary intake at 1 year.69 Furthermore, 
subjects who chose to continue taking orlistat two months 
after the end of the 3-year trial had higher dietary intake of ClinicoEconomics and Outcomes Research 2010:2 submit your manuscript | www.dovepress.com
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fat compared to subjects not taking orlistat. Perhaps this was 
a case of moral hazard, where patients counted on orlistat to 
compensate for increased fat consumption and not complying 
with dietary recommendations. This suggests that orlistat is 
not useful as a self-control device (via adverse side-effects to 
motivate patients to comply with dietary recommendations – 
see below) if side-effects subside after long-term use.
Adverse effects and discontinuation
The use of orlistat has been associated with several 
mild-to-moderate gastrointestinal adverse effects, such as oily 
stools, diarrhea, abdominal pain, and fecal spotting, which 
generally decrease in frequency with ongoing orlistat treat-
ment. The risk-benefit balance may be affected by the duration 
of drug use: cardiovascular benefits are expected only after 
long-term use, whereas the adverse effects tend to occur at 
the beginning of treatment. Another side effect is that orlistat 
interferes with the absorption of fat-soluble   vitamins, as well 
as many drugs (such as warfarin, amiodarone, ciclosporin and 
thyroxine), affecting their bioavailability and effectiveness. 
More serious but less common   conditions associated with the 
liver have been reported, such as   cholelithiasis, cholostatic 
hepatitis and subacute liver failure, as well as acute kidney 
injury and crystal nephropathy.70,71
A recent population-based cohort study in the Netherlands 
found that both cardiovascular and psychiatric comorbidities 
were more prevalent among patients starting antiobesity 
drug treatment, including orlistat, compared to nonstarters. 
This increased prevalence of comorbidities constitutes a 
baseline risk which may translate in higher occurrence of 
psychiatric and cardiovascular diseases during the use of the 
drugs, independent of the drugs. In this study, 77.7% of the 
patients stopped using antiobesity drugs within 90 days.72 
This rate is higher than the discontinuation rate reported by 
prescription-event monitoring studies on orlistat in the UK,73 
where 30.3% of users of orlistat stopped the use in 3 months. 
The nonreimbursement status of the antiobesity drugs in the 
Netherlands may have contributed to this difference.
In the 4-year XENDOS RCT study, 52% of   orlistat-treated 
patients completed treatment compared with 34% of placebo 
recipients.32 Higher attrition in the placebo group was   perhaps 
because control participants became unblinded due to fewer 
gastrointestinal adverse events and had weight loss   expectations 
that were not being fulfilled.30,74 The persistence rates in the 
general population, outside the RCT setting, are even poorer. 
A recent study created an inception cohort of nearly 17,000 
orlistat users, based on population-based administrative data. 
The observed one-year persistence rates were ,10%, and the 
2-year persistence rates were only 2%.75
Attrition has an impact on evaluation of the drug’s 
effectiveness. Last outcome-carried-forward data may have 
variable effects on measured outcomes, depending on when 
the participant dropped out. If drug treatment was effective 
and the participant dropped out early after achieving minimal 
weight loss, final outcomes would be biased toward the null 
effect. If participants dropped out after 4 to 6 months in the 
longer follow-up studies, however, their departure weight 
might have been lower than it would have been had they 
completed the study, as weight loss with pharmacotherapy 
tends to plateau at 6 months.30
Use of orlistat in clinical practice
There is limited population-based data on diet,   physical   activity 
behaviors, and weight loss among users of   prescription weight 
loss medications. The best results with orlistat seem to be 
obtained when it is combined with an intensive group program 
of lifestyle modification.76–78 An analysis of data from the 
1998 US Behavioral Risk Factor Surveillance System found 
that 10.2% of obese women and 3.1% of obese men reported 
using prescription weight loss medications in the past 2 years. 
Among current prescription weight loss medication users, 
only 26.7% reported both eating fewer calories and meeting 
recommended leisure-time physical activity. Of those meeting 
both recommendations, almost half (47.2%) had lost 10% of 
their pretreatment body weight. Of current users, 9% reported 
using the medications for weight maintenance.78
Physicians’ training and attitudes with regard to obesity 
treatment have recently been studied.78,79 Physicians see 
an estimated 25% of the US population every month80 and 
overweight and obese patients represent approximately 60% 
of this patient population.81 However, only 56% of surveyed 
physicians felt qualified to treat obesity, 46% felt success-
ful in this realm, more than 40% had a negative reaction 
towards the appearance of obese patients, and 18% felt 
uncomfortable when examining an obese patient.79 Patients 
who reported receiving physician counseling about weight 
loss were up to two times more likely to report that they 
were currently trying to lose weight.82,83 Based on a 2006 
survey of 256 patients,84 only 65% of obese patients reported 
receiving advice to lose weight, while according to the 1996 
survey of the Behavioral Risk Factor Surveillance System, 
less than half of obese patients reported that their health care 
professional advised them to lose weight.82,83 In a recent phy-
sicians’ survey, however, the majority of physicians (75.5%) ClinicoEconomics and Outcomes Research 2010:2 submit your manuscript | www.dovepress.com
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reported ‘always’ or ‘nearly always’ addressing weight 
control issues with their overweight and obese patients.85 
This may indicate miscommunication among physicians and 
patients, although it appears that over the years the number of 
physicians who advise patients to lose weight has increased. 
The most common recommended weight-control strategies 
were increasing physical activity, reducing consumption 
of fast foods, reducing portion sizes, and reducing soda 
consumption. Weight loss medications were rarely advised. 
Consistent with an earlier study,86 physicians reported high 
expectations for weight loss among their obese patients, with 
a 21.5% weight loss being ‘acceptable’ and a 10.6% weight 
loss, ‘disappointing’.85 These high expectations are consistent 
with and may, in part, reflect most patients’ notoriously high 
weight loss expectations.87,88 Nonetheless, these findings are 
surprising in light of the scientific consensus that as little 
as a 5% to 10% weight loss is associated with significant 
health benefits.24
Realizing the importance of physician training, 
  GlaxoSmithKline (GSK) partnered with the American 
Dietetic Association and the American Pharmaceutical 
  Association on education programs for doctors when launch-
ing the over-the counter version of orlistat, Alli (GSK, 
Brentford, Middlesex, United Kingdom). GSK presented the 
diet drug less as a pill than a lifestyle, and claimed that up to 
50% greater weight reduction would be possible compared to 
diet and exercise alone, but only if people undergoing treat-
ment with Alli stick to a strict regimen of diet and exercise 
as well.89
Economic considerations
The economic approach stresses that health promotion out-
comes are determined in part by the forces of consumer demand 
and producer supply. Consumer demand for   health-related 
goods inevitably involves tradeoffs between health and other 
desirables. For example, to purchase   medication, consumers 
spend money that could have been used to buy other goods 
and services. To exercise, consumers may have to give up 
time spent in sedentary leisure activity.
The supply side of health promotion includes   providers 
of health-related goods and services, the   pharmaceutical 
  industry, healthcare providers, and health insurers. 
  Developments in these markets have been the result of 
the interplay between producers and regulators. As long 
as   market mechanisms and enforcement of deceptive 
  advertising laws sufficiently discourage deceptive claims, 
the pressures   created by   competition should push produc-
ers to improve their products in dimensions that consumers 
value, and improve the information environment in which 
consumers make product choices.90 However, advertisements 
of orlistat generally associate its use with losing several 
dress sizes, contributing to unrealistic expectations. Many 
consumers who start using orlistat soon discontinue its use 
generally because of unmet weight loss expectations and 
side effects.
Another economic aspect of orlistat use is the   question of 
who bears the costs associated with treatment.   Reimbursement 
of drug charges may impact consumers’ demand for obesity 
treatments. While the costs of lifestyle changes are fully 
covered by the obese person, in terms of time spent on 
physical activity or disutility of dieting, the costs of drugs 
become lower to the obese person when they are covered by 
insurance. This may change an obese person’s preference in 
favor of drug treatment.
Cost-effectiveness of orlistat
The incremental cost-effectiveness of orlistat has been 
assessed in many countries, including Italy, the Netherlands, 
Sweden, the United Kingdom, and the United States. A recent 
systematic review and meta-analysis of economic   evaluations 
of weight loss drug treatments included 14 articles, of which 
9 were on orlistat.91 Physical activity was considered only 
in 2 studies, in the United States92 and Italy,93 as part of 
the comparator lifestyle modification (diet plus physical 
  activity). Time horizons varied from the treatment period 
only (1–4 years) to 80 years. Recent studies had longer time 
horizons and modeled effects of long-term sequelae, whereas 
the time horizons of early studies included only the treatment 
years. Longer studies modeled effects on diabetes, micro- and 
macrovascular complications, coronary heart disease, and 
death. The median incremental cost-effectiveness ratio was 
16,000 euros per quality-adjusted life year (QALY) (range, 
10,000–88,000), with the worst cost-effectiveness occurring 
when recommended stop rules for nonresponding patients 
were not applied. All studies but three were funded by the 
manufacturing company, and the median incremental cost-
effectiveness ratio was considerably higher for independent 
than for sponsored analyses (62,000 euros vs 15,000 euros/
QALY). However, two of the three independent cost utility 
analyses did not use recommended stop rules, as compared 
with one of eight manufacturer-sponsored analyses. Although 
most of the reported incremental cost-effectiveness ratios for 
orlistat seemed to be within acceptable range, some studies 
recommended low-calorie diets94 or varying combinations of ClinicoEconomics and Outcomes Research 2010:2 submit your manuscript | www.dovepress.com
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diet, physical activity, and behavior modification95 as better 
options for combating obesity.
The results of cost-effectiveness analyses were most 
sensitive to assumptions regarding weight loss sustainability 
and utility per kilogram lost.91 Restricting orlistat treatment 
to specific groups and the cost of doctor’s visits were also 
important. Foxcroft96 compared the cost-utility of orlistat 
treatment under two treatment criteria: 1) criteria from 
recent guidance from the UK National Institute for Clinical 
Excellence (NICE), which recommended stopping treatment 
if weight loss was less than 5% at Month 3, and less than 
10% at Month 6; and 2) criteria from the European Agency 
for the Evaluation of Medicinal Products (EMEA) license 
for orlistat prescription in the European community which 
recommended stopping treatment if weight loss was less than 
5% at 3 months. The costs per QALY gained for the EMEA 
criteria were £19,005 compared to £24,431 when NICE cri-
teria were applied. Both of these results were better than a 
previous estimate of £45,881 per QALY,97 reflecting the more 
restrictive criteria for the continued use of orlistat, as well 
as taking into account that prescriptions were almost always 
provided by general practitioners rather than more expensive 
hospital specialists. The finding that EMEA criteria resulted 
in a more favorable estimate indicated that the NICE criteria 
may have narrowed the treatment population too far.96
No study was available on cost-effectiveness of Alli. Given 
that the Alli dosage is only half of the prescription-strength 
orlistat dosage (60 mg vs 120 mg), its cost-  effectiveness 
may be less favorable because of lower effectiveness. On 
the other hand, because Alli is not a prescription drug, the 
overall cost of treatment by Alli is lower, which will improve 
its cost-effectiveness.
Use of orlistat in children  
and adolescents
Overweight in adolescence is associated with increased 
early all-cause and coronary heart disease mortality rates in 
adult men and increased risks for coronary heart disease and 
  atherosclerosis in both adult men and adult women.98–103
In 2003, orlistat was approved for use in 12–18 year old 
adolescents in the United States and later in the European 
Union. In children younger than 12 years, drug treatment 
may be used only in exceptional circumstances, if severe 
life-threatening comorbidities (such as sleep apnea or raised 
intracranial pressure) are present,23 and only if a formal 
  program of intensive lifestyle modification has failed. In 
general, children with a BMI below the 95th percentile should 
not be treated with antiobesity drugs.104
Several limitations discourage physicians from early 
  implementation of drug therapies: 1) the limited and 
  inconclusive nature of data supporting the use of pharma-
cological therapy for pediatric overweight, especially that 
long-term effects are unknown;105,106 2) reduced efficacy of 
antiobesity drugs over time, with a plateau after 6 months of 
treatment, an effect also noted with hypocaloric diets;101 3) the 
complexity of weighing the relative risk of severe adverse 
events in children against the long-term potential for 
  obesity-related morbidity and mortality; and 4) the likelihood 
that drug therapy will have higher lifetime risks and costs 
than behavioral interventions.
A recent meta-analysis of treatment of pediatric obesity 
showed that orlistat was associated with a significant fall 
in BMI of 0.7 kg/m2, but treatment was associated with 
increased rates of gastrointestinal side effects, includ-
ing abdominal discomfort, pain, and steatorrhea.107,108 
Side effects were usually mild to moderate and generally 
decreased in frequency with continued treatment. A major 
concern,   especially for growing adolescents, is the poten-
tial decrease in absorption of fat soluble vitamins. Finally, 
orlistat must be taken with each meal, thus reducing its 
utility in children because they are often in school during 
lunchtime.108
Children with psychiatric illness are at greater risk for 
obesity than those in the general population. In part, this 
greater risk is due to the escalating use of psychotropic 
medications.109 Because there are only limited intervention 
studies available for obese children with psychiatric illnesses, 
general childhood obesity studies should be referenced for 
trials in this population.
Discussion and concluding 
comments
Antiobesity drugs are commonly used population-wide and 
they generate hundreds of million dollars in annual sales. 
Weight reduction by current antiobesity drugs compared to 
placebo is at most around 5 kg. The drug orlistat is associated 
with the least-severe adverse effects, but compared with other 
drugs in its class it also delivers the most modest weight loss 
versus placebo (less than 3 kg).31–33,110
In general, orlistat appears to have a favorable risk/benefit 
profile, and most of the estimated cost-effectiveness ratios 
seem to be within the range that is generally considered 
acceptable. In the short term, orlistat is associated with lower 
diabetes incidence and slightly improved blood pressure and 
lipid profiles. It has also been found to have a beneficial effect 
on nonalcoholic fatty liver disease.70ClinicoEconomics and Outcomes Research 2010:2 submit your manuscript | www.dovepress.com
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Questions remain regarding whether improvements in risk 
factors may occur in all obese persons or only in high-risk 
groups, whether orlistat affects general morbidity and mortality 
in treated populations, and whether weight loss studies are appli-
cable to the everyday clinical management of obese patients. Few 
studies on orlistat have had longer than 3 years of follow-up, 
whereas studies of hypertension or diabetes management typi-
cally have 4–8 years of follow-up to assess potential improve-
ments in cardiovascular outcomes.111 Losses to follow-up were 
typically 30%–60%, whereas less than 20% loss to follow-up 
is a minimum requirement for clinical trials. Gastrointestinal 
side effects also limit the applicability of the results in clinical 
practice. Therapy is regarded as a long-term necessity because 
weight regain invariably follows drug discontinuation.29,30 How-
ever, weight loss plateau and weight regain occur even when 
orlistat treatment was continued beyond one year.68
Given the very low continuation with orlistat treatment 
in the population – less than 10% the first year and only 2% 
in the second year75 – orlistat may not have a significant 
impact on the obesity epidemic. Sibutramine, the other drug 
approved both in the United States and Europe, is slightly 
more effective but has more serious side effects. The new 
generation of antiobesity drugs will not be available in the 
near future. Some hope exists for miracle drugs, such as 
the recent discovery of the ‘exercise pill’ known as AICAR 
(5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside); 
however, no pharmaceutical agent with a single molecular 
target will be able to produce all the beneficial effects that 
physical activity can: exercise has multisystem effects.112,113 
In 2008 several community-based physical   activity interven-
tions were shown to offer good value for money, with cost-
effectiveness ratios ranging between $14,000 and $69,000 
US dollars per QALY gained.114
Educating physicians and patients about health benefits 
of even modest weight loss may improve population-wide 
continuation with antiobesity treatment, including the appro-
priate use of orlistat in conjunction with diet and physical 
activity. In addition, improving environmental and social 
factors and establishing community programs that promote 
healthy lifestyles remain essential to fostering healthier food 
choices and increasing physical activity.
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